STOP-HER2: Stopping Trastuzumab in HER2+ MBC
Public ClinicalTrials.gov record NCT05721248. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients With HER2+ Metastatic Breast Cancer
Study identification
- NCT ID
- NCT05721248
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Enrollment
- 82 participants
Conditions and interventions
Interventions
- Cessation of anti-HER2 treatment Other
Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 18, 2023
- Primary completion
- May 31, 2026
- Completion
- May 31, 2036
- Last update posted
- Feb 19, 2026
2023 – 2036
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Hospital Arizona | Phoenix | Arizona | 85054 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 02809 | — |
| Mayo Clinical Hospital Florida | Jacksonville | Florida | 32224 | — |
| Dana-Farber Cancer Insitute | Boston | Massachusetts | 02215 | — |
| DFCI @ Foxborough | Foxborough | Massachusetts | 02035 | — |
| DFCI @ Merrimack Valley | Methuen | Massachusetts | 01844 | — |
| DFCI @ Milford Regional Hospital | Milford | Massachusetts | 01757 | — |
| DFCI @ South Shore Hospital | South Weymouth | Massachusetts | 02190 | — |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905 | — |
| Duke University | Durham | North Carolina | 27710 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15213 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05721248, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 19, 2026 · Synced May 15, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05721248 live on ClinicalTrials.gov.